JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotger, M.
Right arrow Articles by Patel, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotger, M.
Right arrow Articles by Patel, R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2005, p. 4266-4268, Vol. 43, No. 8
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.8.4266-4268.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Phenotypic and Genotypic Mupirocin Resistance among Staphylococci Causing Prosthetic Joint Infection

Margalida Rotger,1 Andrej Trampuz,1 Kerryl E. Piper,1 James M. Steckelberg,1 and Robin Patel1,2*

Division of Infectious Diseases, Department of Internal Medicine,1 Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota2

Received 10 December 2004/ Returned for modification 9 February 2005/ Accepted 19 April 2005


   ABSTRACT
Top
 Abstract
Text
 References
 
Mupirocin MICs and mupA presence were determined in 108 staphylococci causing prosthetic joint infection. Zero of 35 isolates (0%) of methicillin-susceptible Staphylococcus aureus, 4/15 (27%) methicillin-resistant S. aureus isolates, 3/16 (19%) methicillin-susceptible coagulase-negative staphylococci, and 11/42 (26%) methicillin-resistant coagulase-negative staphylococci were mupirocin resistant. mupA was detected in all five high-level mupirocin-resistant staphylococci and one mupirocin-susceptible staphylococcus.


   TEXT
Top
 Abstract
 Text
References
 
Most Staphylococcus aureus infections appear to originate from endogenous nasal flora (1, 10, 24). Decolonization of nasal carriers prior to orthopedic surgery may reduce the incidence of surgical site infection caused by S. aureus and the subsequent development of prosthetic joint infection (PJI) (9, 26). Topical mupirocin is an effective S. aureus nasal decolonization agent (14, 21); however, mupirocin resistance may be associated with decolonization failure (4, 7, 25). Low-level resistance to mupirocin is associated with mutations in endogenous bacterial isoleucyl-tRNA synthetase; high-level mupirocin resistance is due to acquisition of mupA which encodes an exogenous isoleucyl-tRNA synthetase not inhibited by mupirocin (6, 8). Coagulase-negative staphylococci (CNS) may act as a reservoir for mupA, which may be transferred to S. aureus; transfer of mupA from CNS to S. aureus has been demonstrated in vitro (17, 23).

To determine the frequency of phenotypic and genotypic resistance to mupirocin, we collected staphylococci from patients who had infected knee or hip prostheses and were hospitalized at the Mayo Clinic, Rochester, Minn., between January 1999 and December 2002. One staphylococcal isolate per patient from the site of the infection was studied. PJI was defined by the presence of at least one of the following criteria: (i) growth of the same microorganism in two or more synovial fluid or intraoperative tissue cultures, (ii) synovial fluid or intraoperative tissue purulence, (iii) acute inflammation on histopathologic examination of intraoperative tissue, and (iv) a sinus tract communicating with the prosthesis (22, 28).

Mupirocin MICs were determined by broth microdilution according to Clinical and Laboratory Standards Institute (formerly NCCLS) guidelines (15). Mupirocin resistance was classified as low level (MIC, 8 to 256 µg/ml) or high level (MIC, >256 µg/ml) (3). S. aureus ATCC 29213 was used for assay control.

The presence of mupA was determined by using PCR with previously described primers Mup 1 (5' CCC ATG GCT TAC CAG TTG A) and Mup 2 (5' CCA TGG AGC ACT ATC CGA A) (8, 18). DNA was extracted from 108 bacterial cells by using DNA Stat DNA-60 (Tel-Test, Friendswood, TX). Cycling parameters consisted of 95°C for 10 min followed by 40 cycles of 1 min at 94°C, 2 min at 46°C, and 3 min at 72°C, with a final extension of 3 min at 72°C.

To evaluate differences in categorical variables between groups, the two-tailed Fisher's exact test was used. A P value of <0.05 was considered statistically significant. All calculations were performed using the statistical software package JMP (version 5.1; SAS Institute Inc., Cary, NC). The study was approved by the Mayo Clinic Institutional Review Board.

A total of 108 staphylococcal isolates from 57 men and 51 women (median age, 70 years; range, 17 to 90 years) with infected knee (n = 61) or hip (n = 47) prostheses were studied. Fifty isolates (46%) were S. aureus isolates and 58 isolates (54%) were CNS, including Staphylococcus epidermidis (n = 45), Staphylococcus lugdunensis (n = 6), Staphylococcus caprae/capitis (n = 2), Staphylococcus warneri (n = 2), Staphylococcus hominis (n = 1), Staphylococcus simulans (n = 1), and Staphylococcus saprophyticus (n = 1). Coagulase-negative staphylococci were identified to the species level by using conventional biochemical testing. For isolates for which identification was unclear by use of conventional biochemical testing, 16S ribosomal RNA gene PCR and bidirectional sequence analysis were performed, as previously described (11). Data were analyzed by use of Sequencher 3.1 (Gene Codes Corporation, Ann Arbor, MI) and GenBank.

Table 1 shows the distribution of mupirocin resistance among staphylococcal isolates. Phenotypic mupirocin resistance was more common among CNS (14 of 58 isolates, 24%) than among S. aureus isolates (4 of 50 isolates, 8%) (P = 0.037). Among the 35 methicillin-susceptible S. aureus isolates, no mupirocin resistance was detected, whereas 4 of 15 (27%) methicillin-resistant S. aureus (MRSA) isolates were resistant to mupirocin (P = 0.006). Three MRSA isolates exhibited low-level mupirocin resistance (mupirocin MICs were 8, 32, and 32 µg/ml), and one exhibited high-level mupirocin resistance. Among CNS, 3 of 16 (19%) methicillin-susceptible isolates and 11 of 42 (26%) methicillin-resistant isolates exhibited mupirocin resistance (P = 0.736). Two methicillin-susceptible CNS exhibited low-level mupirocin resistance (mupirocin MICs were 32 and 64 µg/ml), and one exhibited high-level mupirocin resistance. In contrast, eight methicillin-resistant CNS exhibited low-level mupirocin resistance (mupirocin MICs were 32 µg/ml [six isolates] and 64 µg/ml [two isolates]), and three exhibited high-level mupirocin resistance.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Phenotypic and genotypic mupirocin resistance in staphylococci causing prosthetic joint infection

 
mupA was detected in all isolates exhibiting high-level mupirocin resistance, as well as in one mupirocin-susceptible (mupirocin MIC, 2 µg/ml) S. epidermidis isolate. PCR amplification and product sequence analysis confirmed the presence of a mupA-specific sequence in this mupirocin-susceptible S. epidermidis isolate (GenBank accession number X75439) (8).

In our study, mupirocin resistance was more prevalent in CNS than in S. aureus (24% versus 8%), as was previously shown in studies with bloodstream, nosocomial pneumonia, skin and soft tissue infection, environmental, and carriage isolates (12, 13, 16, 20, 27). We also found that the mupirocin resistance rate among methicillin-resistant staphylococci causing PJI was higher than that of methicillin-susceptible staphylococci causing PJI, especially among S. aureus isolates (i.e., 27% in MRSA isolates versus 0% in methicillin-susceptible S. aureus isolates). This finding has been previously reported (2, 12, 20, 27); however, our study is the first to include a defined group of individuals with PJI. The presence of mupA in our study did not consistently correlate with high-level mupirocin resistance. mupA has been previously reported among S. aureus isolates exhibiting low-level mupirocin resistance (5, 18, 19) but not (as reported herein) in mupirocin-susceptible S. epidermidis. mupA may be present but not expressed, potentially as a result of mutations outside of the region sequenced herein or inadequate gene copy (18).

In conclusion, mupirocin resistance was found in 27% of MRSA isolates causing hip or knee PJI. This finding is important because mupirocin is used for decolonization of MRSA carriers, including the prevention of infection after implantation of prosthetic devices. Mupirocin susceptibility testing of S. aureus isolates to be treated with mupirocin is advised. New strategies for MRSA nasal decolonization are warranted.

(This work was presented in part at the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, Ill., 14 to 17 September 2003.)


   ACKNOWLEDGMENTS
 
This study was supported in part by the Spanish Society of Infectious Diseases and Clinical Microbiology (Madrid, Spain) and the Mayo Foundation.


   FOOTNOTES
 
* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905. Phone: (507) 255-6482. Fax: (507) 284-9066. E-mail: patel.robin{at}mayo.edu. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Chang, F. Y., N. Singh, T. Gayowski, S. D. Drenning, M. M. Wagener, and I. R. Marino. 1998. Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation 65:1169-1172.[CrossRef][Medline]
  2. Chaves, F., J. Garcia-Martinez, S. de Miguel, and J. R. Otero. 2004. Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples. J. Clin. Microbiol. 42:822-824.[Abstract/Free Full Text]
  3. Cookson, B. D. 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. 41:11-18.[Abstract/Free Full Text]
  4. Decousser, J. W., P. Pina, J. C. Ghnassia, J. P. Bedos, and P. Y. Allouch. 2003. First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin. Eur. J. Clin. Microbiol. Infect. Dis. 22:318-319.[Medline]
  5. Fujimura, S., A. Watanabe, and D. Beighton. 2001. Characterization of the mupA gene in strains of methicillin-resistant Staphylococcus aureus with a low level of resistance to mupirocin. Antimicrob. Agents Chemother. 45:641-642.[Free Full Text]
  6. Gilbart, J., C. R. Perry, and B. Slocombe. 1993. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob. Agents Chemother. 37:32-38.[Abstract/Free Full Text]
  7. Harbarth, S., S. Dharan, N. Liassine, P. Herrault, R. Auckenthaler, and D. Pittet. 1999. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1412-1416.[Abstract/Free Full Text]
  8. Hodgson, J. E., S. P. Curnock, K. G. Dyke, R. Morris, D. R. Sylvester, and M. S. Gross. 1994. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob. Agents Chemother. 38:1205-1208.[Abstract/Free Full Text]
  9. Kalmeijer, M. D., E. van Nieuwland-Bollen, D. Bogaers-Hofman, and G. A. de Baere. 2000. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect. Control Hosp. Epidemiol. 21:319-323.[CrossRef][Medline]
  10. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.[Abstract]
  11. Kolbert, C., P. Rys, M. Hopkins, D. Lynch, J. Germer, C. O'Sullivan, A. Trampuz, and R. Patel. 2004. 16S ribosomal DNA sequence analysis for identification of bacteria in a clinical microbiology laboratory. In D. Persing, F. Tenover, J. Versalovic, Y. Tang, E. Unger, D. Relman, and T. White (ed.), Molecular microbiology: diagnostic principles and practice. ASM Press, Washington, D.C.
  12. Kresken, M., D. Hafner, F. J. Schmitz, and T. A. Wichelhaus. 2004. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int. J. Antimicrob. Agents 23:577-581.[CrossRef][Medline]
  13. Leski, T. A., M. Gniadkowski, A. Skoczynska, E. Stefaniuk, K. Trzcinski, and W. Hryniewicz. 1999. Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. J. Clin. Microbiol. 37:2781-2788.[Abstract/Free Full Text]
  14. Mody, L., C. A. Kauffman, S. A. McNeil, A. T. Galecki, and S. F. Bradley. 2003. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37:1467-1474.[CrossRef][Medline]
  15. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. NCCLS, Wayne, Pa.
  16. Petinaki, E., I. Spiliopoulou, F. Kontos, M. Maniati, Z. Bersos, N. Stakias, H. Malamou-Lada, C. Koutsia-Carouzou, and A. N. Maniatis. 2004. Clonal dissemination of mupirocin-resistant staphylococci in Greek hospitals. J. Antimicrob. Chemother. 53:105-108.[Abstract/Free Full Text]
  17. Rahman, M., S. Connolly, W. C. Noble, B. Cookson, and I. Phillips. 1990. Diversity of staphylococci exhibiting high-level resistance to mupirocin. J. Med. Microbiol. 33:97-100.[Abstract]
  18. Ramsey, M. A., S. F. Bradley, C. A. Kauffman, and T. M. Morton. 1996. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob. Agents Chemother. 40:2820-2823.[Abstract]
  19. Ramsey, M. A., S. F. Bradley, C. A. Kauffman, T. M. Morton, J. E. Patterson, and D. R. Reagan. 1998. Characterization of mupirocin-resistant Staphylococcus aureus from different geographic areas. Antimicrob. Agents Chemother. 42:1305. (Letter.)[Free Full Text]
  20. Schmitz, F. J., E. Lindenlauf, B. Hofmann, A. C. Fluit, J. Verhoef, H. P. Heinz, and M. E. Jones. 1998. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob Chemother. 42:489-495.[Abstract/Free Full Text]
  21. Tomic, V., P. Svetina Sorli, D. Trinkaus, J. Sorli, A. F. Widmer, and A. Trampuz. 2004. Comprehensive strategy to prevent nosocomial spread of methicillin-resistant Staphylococcus aureus in a highly endemic setting. Arch. Intern. Med. 164:2038-2043.[Abstract/Free Full Text]
  22. Trampuz, A., D. R. Osmon, A. D. Hanssen, J. M. Steckelberg, and R. Patel. 2003. Molecular and antibiofilm approaches to prosthetic joint infection. Clin. Orthop. Relat. Res. 2003:69-88.
  23. Udo, E. E., L. E. Jacob, and E. M. Mokadas. 1997. Conjugative transfer of high-level mupirocin resistance from Staphylococcus haemolyticus to other staphylococci. Antimicrob. Agents Chemother. 41:693-695.[Abstract]
  24. von Eiff, C., K. Becker, K. Machka, H. Stammer, G. Peters, et al. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344:11-16.[Abstract/Free Full Text]
  25. Walker, E. S., J. E. Vasquez, R. Dula, H. Bullock, and F. A. Sarubbi. 2003. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect. Control Hosp. Epidemiol. 24:342-346.[CrossRef][Medline]
  26. Wilcox, M. H., J. Hall, H. Pike, P. A. Templeton, W. N. Fawley, P. Parnell, and P. Verity. 2003. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J. Hosp. Infect. 54:196-201.[CrossRef][Medline]
  27. Yun, H. J., S. W. Lee, G. M. Yoon, S. Y. Kim, S. Choi, Y. S. Lee, E. C. Choi, and S. Kim. 2003. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J. Antimicrob. Chemother. 51:619-623.[Abstract/Free Full Text]
  28. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.[Free Full Text]

Journal of Clinical Microbiology, August 2005, p. 4266-4268, Vol. 43, No. 8
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.8.4266-4268.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rotger, M.
Right arrow Articles by Patel, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rotger, M.
Right arrow Articles by Patel, R.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS